Characterization of NAT, GST, and CYP2E1 Genetic Variation in Sub‐Saharan African Populations: Implications for Treatment of Tuberculosis and Other Diseases

Documenti analoghi

• PharmVar GeneFocus : NAT2 — Genetic Variation and Updated Nomenclature
  di: Georgia Papanikolaou, et al.
  Pubblicazione: (2025)
• Frequency of Key Pharmacogenes CYP2C9 , CYP2C19 , CYP2D6 , and SLCO1B1 in the Yogyakarta Population: Implications for Precision Prescribing in Indonesia
  di: Dwi Aris Agung Nugrahaningsih, et al.
  Pubblicazione: (2026)
• The Burden of Adverse Drug Reactions in Africa in the Context of Pharmacogenetics‐Based Clinical Guidelines
  di: Janine Scholefield, et al.
  Pubblicazione: (2026)
• SLCO1B1 Functional Variants, Bilirubin, Statin‐Induced Myotoxicity, and Recent Sub‐Saharan African Ancestry: A Precision Medicine Health Equity Study
  di: Tanushree Haldar, et al.
  Pubblicazione: (2025)
• An Update to the Clinical Pharmacogenetics Implementation Consortium ( CPIC ) SLCO1B1 Allele Functionality Table Leveraging Evidence from Participants of Predominantly Sub‐Saharan African Ancestry
  di: Akinyemi Oni‐Orisan, et al.
  Pubblicazione: (2025)